Qiagen (NYSE: QGEN) — Perfil da empresa, notícias e dados financeiros
Qiagen is a global provider of sample and assay technologies for molecular diagnostics and life sciences research.
Qiagen
Qiagen is a global provider of Sample to Insight solutions that enable life science researchers and healthcare providers to extract valuable molecular insights from biological materials. The company develops and manufactures sample technologies that isolate and purify DNA, RNA and proteins from blood, tissue and other samples. Its assay technologies convert these purified samples into testable formats, while automated instruments integrate laboratory processing workflows. Qiagen also offers bioinformatics software and curated databases to analyze and interpret genomic data. The company serves customers across molecular diagnostics, academic research, biotechnology, pharmaceutical development and forensic science globally.
Resumo
Operações
Produtos e/ou serviços de Qiagen
- Sample Technologies: Consumable reagents, membrane columns and automated processing systems used to isolate, purify and stabilize DNA, RNA and proteins from human, animal and environmental biological samples prior to downstream molecular analysis.
- Diagnostic Solutions and Syndromic Testing: Molecular diagnostic assays and automated test platforms deployed in clinical laboratories for latent tuberculosis screening, multiplexed respiratory infection panels, precision oncology marker detection and reproductive health testing across global healthcare networks.
- Digital PCR Systems: Nanoplate-based digital polymerase chain reaction instruments, reagents and assay panels that deliver automated absolute quantification of gene expression, rare mutations and copy number variations in research and diagnostic laboratories.
- Next-Generation Sequencing Workflows: Targeted gene panels, enzymatic library preparation kits and automated sequence analysis pipelines utilized for microbial pathogen surveillance, liquid biopsy biomarker discovery, solid tumor characterization and translational genomic research.
- Human Identification and Forensics: Specialized sample extraction reagents, short tandem repeat assay kits and liquid handling instruments used by government law enforcement agencies, forensic laboratories and disaster recovery units for human identity testing.
- Bioinformatics and Clinical Decision Software: Enterprise cloud software, curated genomic knowledge databases and algorithmic interpretation tools that process, analyze and report complex next-generation sequencing data for clinical diagnostics, academic research and pharmaceutical drug discovery.
equipe executiva do Qiagen
- Roland SackersCFO, MD & Member of Management Board
- Jonathan M. PrattCEO & Member of Management Board
- Antonio SantosSenior VP & Head of Global Operations
- Daniel WendorffVP & Head of Investor Relations
- John GilardiVP & Head of Corporate Communications
- Stephany FosterSenior VP & Head of Human Resources
- Thomas SchweinsSenior Vice President of Life Science Business Area
- Thomas TheuringerSenior Director & Head of External Communications
- Jean-Pascal ViolaSenior VP & Head of Corporate Strategy and Business Development
- Nitin SoodSenior VP & Head of Product Portfolio & Innovation
Últimas notícias sobre a Qiagen
Histórico de dividendos
Dividendos por ação pagos pela Qiagen , por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2026(até o momento) | — | — | — | $4.7005 |
| FY2025 | — | — | — | $1.6142 |
| FY2024 | — | — | — | $1.3166 |
| FY2017 | — | — | — | $1.1028 |
| FY2002 | — | — | — | $0.0320 |
Principais indicadores financeiros
Resultados divulgados pela Qiagen , em USD.
- Cap. de mercado
- 10,4 bi
- Receita (TTM)
- 2,1 bi
- P/L
- 25.6
- LPA (diluído, TTM)
- 2.0
- Dividend yield
- 0.7%
- Margem de lucro
- 19.5%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 2,1 bi | 520,3 mi | 424,9 mi | |
| 2 bi | 97,7 mi | 83,6 mi | |
| 2 bi | 409,9 mi | 341,3 mi | |
| 2,1 bi | 531,5 mi | 423,2 mi |